When will retatrutide be available and FDA approved?
Retatrutide remains investigational in July 2026. See the Phase 3 status, likely approval steps, and why products sold online are not approved medicine.
Written and fact-checked by ClearlyMeds Editorial Team. Published July 18, 2026. Last updated July 18, 2026.
This page has not been medically reviewed by a licensed clinician. It is educational content, not medical advice.
Retatrutide is not FDA approved and is not legally available by prescription as of July 18, 2026. Lilly has reported positive Phase 3 results, but remaining trials, a regulatory submission, and FDA review must occur before any commercial launch. Any exact approval date is speculation, and products sold online are not approved retatrutide.
Where development stands
Retatrutide is a once-weekly investigational medicine that activates three hormone pathways. Lilly has announced positive results from pivotal studies, while additional Phase 3 work continues. Successful trial headlines are not the same as approval: regulators still need a complete benefit-risk package, manufacturing information, labeling, and a formal application.
Why there is no reliable launch date yet
The timing depends on when Lilly completes the program and files an application, whether the FDA accepts it, and whether reviewers request more data. A reasonable sequence is trial completion, submission, FDA review, and then manufacturing and pharmacy rollout. ClearlyMeds will update this page when Lilly or the FDA publishes a concrete milestone.
Avoid products claiming to be retatrutide
Because no FDA-approved retatrutide exists, online products marketed for human use cannot be verified against an approved label or supply chain. Research-chemical labels do not make a product safe for self-injection. Patients interested in experimental treatment should use registered clinical trials and discuss eligibility with a licensed clinician.
ClearlyMeds bottom line
Retatrutide is promising but still investigational. There is no approved prescription product, legitimate retail price, or confirmed launch date in July 2026. Treat specific approval-date or price claims as estimates until Lilly and the FDA publish them.
Retatrutide status as of July 18, 2026
| Milestone | Status | Meaning |
|---|---|---|
| Phase 3 program | In progress | Pivotal data are still being completed |
| FDA approval | Not approved | No approved prescribing label exists |
| Retail availability | Not available | No legitimate commercial product or price |
| Next reliable signal | Company filing or FDA acceptance | A formal review process can then begin |
Related provider reviews
ClearlyMeds connects this answer to the provider reviews most relevant to the decision.
Sources
- What to know about retatrutide — Eli Lilly and Company
- Retatrutide obesity study — ClinicalTrials.gov
Frequently asked questions
Can a doctor prescribe retatrutide now?
No. Retatrutide is not FDA approved or commercially available by prescription as of July 18, 2026.
Has retatrutide completed Phase 3 trials?
Lilly has reported positive pivotal results, but the broader Phase 3 program and regulatory process are not complete.
Is research-grade retatrutide safe to use?
ClearlyMeds cannot recommend it. Research products are not FDA-approved medicines and may have uncertain identity, strength, sterility, and handling.